{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Therapeutic+Proteins&page=13",
    "query": {
      "condition": "Therapeutic Proteins",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 1350,
    "total_pages": 135,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Therapeutic+Proteins&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Therapeutic+Proteins&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T13:46:38.600Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03041363",
      "title": "Treatment Development of Triheptanoin (G1D)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epilepsy",
        "GLUT1DS1",
        "Glut1 Deficiency Syndrome 1, Autosomal Recessive",
        "Glucose Metabolism Disorders",
        "Glucose Transport Defect",
        "Glucose Transporter Type 1 Deficiency Syndrome",
        "Glucose Transporter Protein Type 1 Deficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "Triheptanoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Juan Pascual",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "2 Years to 35 Years"
      },
      "enrollment_count": 12,
      "start_date": "2017-03-29",
      "completion_date": "2017-12-22",
      "has_results": false,
      "last_update_posted_date": "2022-12-22",
      "last_synced_at": "2026-10-15T13:46:38.600Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03041363"
    },
    {
      "nct_id": "NCT03015792",
      "title": "Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Plasma Cell Myeloma",
        "Refractory Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2017-03-10",
      "completion_date": "2022-10-18",
      "has_results": false,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-10-15T13:46:38.600Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03015792"
    },
    {
      "nct_id": "NCT00354432",
      "title": "Soy Protein/Effexor Hormone Therapy for Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hot Flashes",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "oral soy protein/isoflavones powder",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Venlafaxine",
          "type": "DRUG"
        },
        {
          "name": "Placebo Powder",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "21 Years and older · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2007-02-01",
      "completion_date": "2010-08-01",
      "has_results": true,
      "last_update_posted_date": "2021-09-28",
      "last_synced_at": "2026-10-15T13:46:38.600Z",
      "location_count": 20,
      "location_summary": "Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00354432"
    },
    {
      "nct_id": "NCT00526058",
      "title": "(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Secura then Futura",
          "type": "DEVICE"
        },
        {
          "name": "Futura then Secura",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "B. Braun Medical Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "25 Years to 70 Years"
      },
      "enrollment_count": 18,
      "start_date": "2007-08",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2018-09-14",
      "last_synced_at": "2026-10-15T13:46:38.600Z",
      "location_count": 2,
      "location_summary": "Hartford, Connecticut • Kansas City, Kansas",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00526058"
    },
    {
      "nct_id": "NCT01687608",
      "title": "Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "AskBio009",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "18 Years to 75 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2013-02-11",
      "completion_date": "2030-01-17",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-10-15T13:46:38.600Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01687608"
    },
    {
      "nct_id": "NCT01760655",
      "title": "Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia With FLT3/ITD Mutation",
        "Acute Myeloid Leukemia With Gene Mutations",
        "Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM",
        "Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214",
        "Aplastic Anemia",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Chronic Myelomonocytic Leukemia",
        "Follicular Lymphoma",
        "Hodgkin Lymphoma",
        "Myelodysplastic Syndrome",
        "Myelofibrosis",
        "Myeloid Leukemia",
        "Non-Hodgkin Lymphoma",
        "Plasma Cell Myeloma",
        "Polycythemia Vera",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Therapy-Related Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Therapeutic Allogeneic Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 62,
      "start_date": "2012-12-24",
      "completion_date": "2022-12-05",
      "has_results": true,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-10-15T13:46:38.600Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01760655"
    },
    {
      "nct_id": "NCT00993694",
      "title": "Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Methemoglobinemia",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Nonmalignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "dapsone",
          "type": "DRUG"
        },
        {
          "name": "medical chart review",
          "type": "OTHER"
        },
        {
          "name": "assessment of therapy complications",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 41,
      "start_date": "2009-01",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2017-04-17",
      "last_synced_at": "2026-10-15T13:46:38.600Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00993694"
    },
    {
      "nct_id": "NCT00697346",
      "title": "Study of MLN8237 in Participants With Advanced Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Follicular Lymphoma",
        "B-cell Marginal Zone Lymphoma",
        "Diffuse Large B-cell Lymphoma",
        "B-cell Mantle Cell Lymphoma",
        "B-cell Small Lymphocytic Lymphoma",
        "B-Cell Chronic Lymphocytic Leukemia",
        "Multiple Myeloma",
        "Waldenstrom's Macroglobulinemia",
        "Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified",
        "Angioimmunoblastic T-cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Enteropathy Associated T-cell Lymphoma",
        "NK Lymphoma"
      ],
      "interventions": [
        {
          "name": "Alisertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2008-07-11",
      "completion_date": "2016-10-19",
      "has_results": true,
      "last_update_posted_date": "2019-05-31",
      "last_synced_at": "2026-10-15T13:46:38.600Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Lexington, Kentucky • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00697346"
    },
    {
      "nct_id": "NCT01352286",
      "title": "Redirected Auto T Cells for Advanced Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Autologous Genetically modified T cells",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 25,
      "start_date": "2011-05-13",
      "completion_date": "2019-07-08",
      "has_results": true,
      "last_update_posted_date": "2019-12-03",
      "last_synced_at": "2026-10-15T13:46:38.600Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01352286"
    },
    {
      "nct_id": "NCT02971969",
      "title": "Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2017-01",
      "completion_date": "2021-11-06",
      "has_results": false,
      "last_update_posted_date": "2022-01-06",
      "last_synced_at": "2026-10-15T13:46:38.600Z",
      "location_count": 3,
      "location_summary": "Little Rock, Arkansas • Gainesville, Florida • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02971969"
    }
  ]
}